Castañeda-Vázquez MA, Castañeda-Vázquez H, Garzón MP, Flores-Martínez N

Language: Spanish
References: 12
Page: 148-156
PDF size: 129.51 Kb.

ABSTRACT

Introduction. Venous ulcers of lower extremities show an incidence of 2.5 million cases annually in the United States of America and a prevalence of 22 per 100 people. They are recurrent, cause incapacity and can also cause ambulatory problems. Topical application of dyphenylhydantoin sodium can favor the scarring of the above mentioned ulcers. Material and Methods. 20 patients with leg ulceration were selected. The diagnosis was posflebitic sequel. We applied topical DFH-Na to the ulcers on a daily basis for 2 to 3 months, after washing with soap and water. The ten remaining patients received conventional treatment (washing with soap and water). General data of the 20 patients: was evaluated sex, age, employment, record of contraception, associated pathologies, ulcer apparition time, relapses. We took biopsies, photographs and carried out planimetric halftion at the beginning and at the end of treatment, elaborating comparative data. Results. We observed that 40% of the patients responde to DFH treatment and in none of the control patients was improvement seen in the healing of flebostatic ulcer. Granulation tissue and epithelial displacement was developed in the DFH-Na group. In the group which received conventional treatment no improvement was observed and 20% developed a light infection. Conclusions. Our results demonstrate the effectiveness of DFH-Na to induce cicatrisation of venous ulcers.

REFERENCES

1. Olivencia JA. Pathophysiology of venous ulcers: surgical implications, review and update. Dermatol Surg 1999;25:880-5.

2. Smith PD. Update on chronic-venous-insufficiencyinduced inflamatory processes. Angiology 2001; 52 (suppl 1): S35-S42.

3. Clement DL. Venous ulcer reappraisal: insights from an international task force. J Vasc Res 1999; 36 (suppl 1): 42-7.

4. Angle N, Bergan JJ. Chronic venous ulcer. Br Med J 1997; 314:1019-23.

5. Dormandy JA. Pharmacologic treatment of venus leg ulcers. J Cardiovasc Pharmacol 1995; 25 (suppl 2):S61-S5.

6. McNamara JO. Fármacos eficaces para el tratamiento de las epilepsias. En Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman-Gilman A, editores. Las bases farmacológicas de la terapéutica. 9ª Ed. México: McGraw-Hill Interamericana; 1997. p. 491-519.

7. Chicani P. Use of sodium phenytoin in the treatmet of periodontal diseases; Actal Odontostomatol 1972; 26: 265-74.

8. Gudmunson C, Lidgren L. Does diphenylhydantoin acelerate healing of fracture in mice. Acta Orthop Scand 1973; 44:640-9.

9. Ariyoshi T, Remmer H. Die wirkung von verschiedene fettfraktionen der leber. Naunyn schieedeberg. Arch Pharm Exp Path 1968; 260:90-1.

10. Bazin S, Delaunay. Action exercee par des substances lathyrogenes sur le collagene des granulomes. CR Acad Sci (Paris) 1972; 274:18-20.

11. Donoff B. The effect of diphenylhydantoin on open wound healing on guinea pigs. J Surg Res 1978; 24: 45-4.

12. Goultschin J, Soshan S. Inhibition of collagen breakdown by diphenylhydantoin. J Biochem Biophys Acta 1980; 631:189-91.